Table 1.
Baseline characteristics of the ACS patients
| Variables | patients (n = 341) |
|---|---|
| Age (years) | 65.8 ± 10.9 |
| Male, n (%) | 253 (63.0) |
| Smoking, n (%) | 67 (19.6) |
| Drinking, n (%) | 6 (1.8) |
| Comorbidity | |
| Hypertension, n (%) | 215 (63.0) |
| Diabetes mellitus, n (%) | 137 (40.1) |
| Dyslipidemia, n (%) | 82 (24.0) |
| Angiographic follow-up (months) | 34.2 ± 17.2 |
| Stent number (mm) | 1.34 ± 0.65 |
| Stent type | |
| Rapamycin, n (%) | 275 (80.6) |
| Everolimus, n (%) | 24 (7.0) |
| Zotamos, n (%) | 28 (8.2) |
| Stent location | |
| LM, n (%) | 15 (3.3) |
| LAD, n (%) | 191 (41.8) |
| LCX, n (%) | 98 (21.4) |
| RCA, n (%) | 153 (33.5) |
| ISR, n (%) | 62/341 (18.2) |
| Average ISR time (month) | 32.8 ± 26.8 |
| ISR rate for vessel | |
| LM, n (%) | 1/15 (6.7) |
| LAD, n (%) | 41/191 (21.5) |
| LCX, n (%) | 19/98 (19.4) |
| RCA, n (%) | 22/153 (14.4) |
| Medication | |
| Statin therapy, n (%) | 321/341 (94.1) |
| Antiplatelet therapy, n (%) | 322/341 (94.4) |
| Clopidogrel | 136 (39.8) |
| Ticagrelor | 172 (50.4) |
| Aspirin | 285 (83.5) |
| Oral anticoagulation, n (%) | 1/341 (0.3) |
| ACEI/ARB, n (%) | 298/341 (87.3) |
LM left main coronary artery, LAD left anterior descending coronary artery, LCX left circumflex artery coronary artery, RCA right coronary artery, ACEI/ARB angiotensin-converting enzyme inhibitor/angiotensin receptor blocker